{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:33:19Z","timestamp":1791005599002,"version":"4.1.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["197728"],"award-info":[{"award-number":["197728"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FBD-193357"],"award-info":[{"award-number":["FBD-193357"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","award":["41027"],"award-info":[{"award-number":["41027"]}],"id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI148379"],"award-info":[{"award-number":["R01AI148379"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI17653"],"award-info":[{"award-number":["R01AI17653"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI174908"],"award-info":[{"award-number":["R01AI174908"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI150322"],"award-info":[{"award-number":["R01AI150322"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI186809"],"award-info":[{"award-number":["R01AI186809"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01AI162242"],"award-info":[{"award-number":["P01AI162242"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1AI164562"],"award-info":[{"award-number":["UM1AI164562"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ViiV"},{"name":"Fonds de Recherche du Qu\u00e9bec-Sant\u00e9"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Heavily treatment-experienced (HTE) people with HIV (PWH) have limited antiretroviral therapy (ART) treatment options, putting them at greater risk of unfavorable human immunodeficiency virus 1 (HIV-1) disease progression. Fostemsavir (BMS-663068) efficiently suppressed viremia and increased CD4 count when combined with other antiretrovirals in HTE PWH. Its active metabolite, temsavir (BMS-626529, GSK2616713), binds a conserved pocket within the envelope glycoprotein (Env) CD4 binding site and prevents CD4-induced conformational changes. Temsavir effect on Env conformation profoundly alters its glycosylation and cleavage, thereby modifying its antigenicity and reducing gp120 shedding. Here we evaluated if fostemsavir treatment in PWH modulated the levels of nonneutralizing gp120 CD4-induced (CD4i) antibodies (Abs) associated with CD4 depletion in vitro and in PWH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We measured the levels of anti-gp120 CD4i Abs in plasma samples taken before and after fostemsavir treatment in HTE participants from the BRIGHTE trial and the PRESTIGIO registry and compared them to those of a control ART-treated group from the SAILING trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We observed a significant decline of anti-gp120 CD4i Abs in the 2 fostemsavir-treated HTE groups, but not in the control group. Moreover, this effect was unique to anti-gp120 CD4i Abs, as no significant changes were observed in the levels of antibodies targeting Gag. Functionally, this decline in CD4i Abs was associated with a reduced capacity of plasma to recognize and eliminate uninfected primary CD4+ T cells coated with soluble gp120.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Altogether, fostemsavir may provide additional immune benefits to PWH, beyond blocking viral entry, by reducing anti-gp120 CD4i Abs levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>NCT04098315, NCT01231516, and NCT02362503.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiaf461","type":"journal-article","created":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T11:50:06Z","timestamp":1758369006000},"page":"247-256","source":"Crossref","is-referenced-by-count":3,"title":["Fostemsavir Decreases the Levels of Anti-gp120 CD4-Induced Antibodies in Heavily Treatment-Experienced People With HIV"],"prefix":"10.1093","volume":"233","author":[{"given":"Mehdi","family":"Benlarbi","sequence":"first","affiliation":[{"name":"Centre de Recherche du Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al , Axe immunopathologie, Montr\u00e9al, Quebec ,","place":["Canada"]},{"name":"D\u00e9partement de Microbiologie, Infectiologie, et Immunologie, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, Quebec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9015-9589","authenticated-orcid":false,"given":"Jonathan","family":"Richard","sequence":"additional","affiliation":[{"name":"Centre de Recherche du Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al , Axe immunopathologie, Montr\u00e9al, Quebec ,","place":["Canada"]},{"name":"D\u00e9partement de Microbiologie, Infectiologie, et Immunologie, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, Quebec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6548-3427","authenticated-orcid":false,"given":"Tommaso","family":"Clemente","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Scientific Institute , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Bourassa","sequence":"additional","affiliation":[{"name":"Centre de Recherche du Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al , Axe immunopathologie, Montr\u00e9al, Quebec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D","family":"Tolbert","sequence":"additional","affiliation":[{"name":"Infectious Disease Division, Department of Medicine, Uniformed Services University of the Health Sciences , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manyu","family":"Prakash","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Chandravanshi","sequence":"additional","affiliation":[{"name":"Infectious Disease Division, Department of Medicine, Uniformed Services University of the Health Sciences , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5213-9624","authenticated-orcid":false,"given":"Andrew","family":"Clark","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzena","family":"Pazgier","sequence":"additional","affiliation":[{"name":"Infectious Disease Division, Department of Medicine, Uniformed Services University of the Health Sciences , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Durand","sequence":"additional","affiliation":[{"name":"Centre de Recherche du Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al , Axe immunopathologie, Montr\u00e9al, Quebec ,","place":["Canada"]},{"name":"Department of Medicine, Faculty of Medicine, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, Quebec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Castagna","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Scientific Institute , Milan ,","place":["Italy"]},{"name":"Vita-Salute University, San Raffaele Scientific Institute , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Finzi","sequence":"additional","affiliation":[{"name":"Centre de Recherche du Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al , Axe immunopathologie, Montr\u00e9al, Quebec ,","place":["Canada"]},{"name":"D\u00e9partement de Microbiologie, Infectiologie, et Immunologie, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, Quebec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"2026031304525736300_jiaf461-B1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(10)60676-9","article-title":"Antiretroviral therapy and management of HIV infection","volume":"376","author":"Volberding","year":"2010","journal-title":"Lancet"},{"key":"2026031304525736300_jiaf461-B2","doi-asserted-by":"crossref","first-page":"e207954","DOI":"10.1001\/jamanetworkopen.2020.7954","article-title":"Comparison of overall and comorbidity-free life expectancy between insured adults with and without HIV infection, 2000\u20132016","volume":"3","author":"Marcus","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026031304525736300_jiaf461-B3","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.7326\/M21-0065","article-title":"Mortality among persons entering HIV care compared with the general U.S. population: an observational study","volume":"174","author":"Edwards","year":"2021","journal-title":"Ann Intern Med"},{"key":"2026031304525736300_jiaf461-B4","first-page":"180","article-title":"Antiretroviral salvage therapy for multiclass drug-resistant HIV-1-infected patients: from clinical trials to daily clinical practice","volume":"13","author":"Imaz","year":"2011","journal-title":"AIDS Rev"},{"key":"2026031304525736300_jiaf461-B5","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1473-3099(06)70550-3","article-title":"Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults","volume":"6","author":"Temesgen","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"2026031304525736300_jiaf461-B6","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/S0140-6736(03)15022-2","article-title":"Treatment of antiretroviral-drug-resistant HIV-1 infection","volume":"362","author":"Deeks","year":"2003","journal-title":"Lancet"},{"key":"2026031304525736300_jiaf461-B7","author":"Food and Drug Administration"},{"key":"2026031304525736300_jiaf461-B8","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12879-024-09122-5","article-title":"Mechanism of action, resistance, interaction, pharmacokinetics, pharmacodynamics, and safety of fostemsavir","volume":"24","author":"Heidary","year":"2024","journal-title":"BMC Infect Dis"},{"key":"2026031304525736300_jiaf461-B9","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1902493","article-title":"Fostemsavir in adults with multidrug-resistant HIV-1 infection","volume":"382","author":"Kozal","year":"2020","journal-title":"N Engl J Med"},{"key":"2026031304525736300_jiaf461-B10","doi-asserted-by":"crossref","first-page":"e740","DOI":"10.1016\/S2352-3018(20)30240-X","article-title":"Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study","volume":"7","author":"Lataillade","year":"2020","journal-title":"Lancet HIV"},{"key":"2026031304525736300_jiaf461-B11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1021\/acs.jmedchem.7b01337","article-title":"Inhibitors of HIV-1 attachment: the discovery and development of temsavir and its prodrug fostemsavir","volume":"61","author":"Meanwell","year":"2018","journal-title":"J Med Chem"},{"key":"2026031304525736300_jiaf461-B12","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/nchembio.2460","article-title":"Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529","volume":"13","author":"Pancera","year":"2017","journal-title":"Nat Chem Biol"},{"key":"2026031304525736300_jiaf461-B13","doi-asserted-by":"crossref","first-page":"e00148-20","DOI":"10.1128\/JVI.00148-20","article-title":"Long-acting BMS-378806 analogues stabilize the state-1 conformation of the human immunodeficiency virus type 1 envelope glycoproteins","volume":"94","author":"Zou","year":"2020","journal-title":"J Virol"},{"key":"2026031304525736300_jiaf461-B14","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nchembio.1623","article-title":"A broad HIV-1 inhibitor blocks envelope glycoprotein transitions critical for entry","volume":"10","author":"Herschhorn","year":"2014","journal-title":"Nat Chem Biol"},{"key":"2026031304525736300_jiaf461-B15","doi-asserted-by":"crossref","first-page":"e0057722","DOI":"10.1128\/mbio.00577-22","article-title":"Temsavir treatment of HIV-1-infected cells decreases envelope glycoprotein recognition by broadly neutralizing antibodies","volume":"13","author":"Boutin","year":"2022","journal-title":"mBio"},{"key":"2026031304525736300_jiaf461-B16","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3390\/v15051189","article-title":"Temsavir modulates HIV-1 envelope conformation by decreasing its proteolytic cleavage","volume":"15","author":"Boutin","year":"2023","journal-title":"Viruses"},{"key":"2026031304525736300_jiaf461-B17","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.chembiol.2023.03.003","article-title":"Temsavir blocks the immunomodulatory activities of HIV-1 soluble gp120","volume":"30","author":"Richard","year":"2023","journal-title":"Cell Chem Biol"},{"key":"2026031304525736300_jiaf461-B18","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ebiom.2015.12.004","article-title":"Small CD4 mimetics prevent HIV-1 uninfected bystander CD4+ T cell killing mediated by antibody-dependent cell-mediated cytotoxicity","volume":"3","author":"Richard","year":"2016","journal-title":"EBioMedicine"},{"key":"2026031304525736300_jiaf461-B19","doi-asserted-by":"crossref","first-page":"e00358-18","DOI":"10.1128\/mBio.00358-18","article-title":"Uninfected bystander cells impact the measurement of HIV-specific antibody-dependent cellular cytotoxicity responses","volume":"9","author":"Richard","year":"2018","journal-title":"mBio"},{"key":"2026031304525736300_jiaf461-B20","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1128\/JVI.02868-14","article-title":"The HIV-1 gp120 CD4-bound conformation is preferentially targeted by antibody-dependent cellular cytotoxicity-mediating antibodies in sera from HIV-1-infected individuals","volume":"89","author":"Veillette","year":"2015","journal-title":"J Virol"},{"key":"2026031304525736300_jiaf461-B21","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1128\/jvi.70.3.1863-1872.1996","article-title":"Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein","volume":"70","author":"Moore","year":"1996","journal-title":"J Virol"},{"key":"2026031304525736300_jiaf461-B22","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.tim.2017.10.007","article-title":"Impact of HIV-1 envelope conformation on ADCC responses","volume":"26","author":"Richard","year":"2018","journal-title":"Trends Microbiol"},{"key":"2026031304525736300_jiaf461-B23","doi-asserted-by":"crossref","first-page":"105856","DOI":"10.1016\/j.ebiom.2025.105856","article-title":"CD4 T cell counts are inversely correlated with anti-cluster A antibodies in antiretroviral therapy-treated PLWH","volume":"118","author":"Benlarbi","year":"2025","journal-title":"EBioMedicine"},{"key":"2026031304525736300_jiaf461-B24","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1089\/aid.2009.0290","article-title":"Detection of HIV gp120 in plasma during early HIV infection is associated with increased proinflammatory and immunoregulatory cytokines","volume":"26","author":"Rychert","year":"2010","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2026031304525736300_jiaf461-B25","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/infdis\/jiad503","article-title":"Plasma human immunodeficiency virus 1 soluble glycoprotein 120 association with correlates of immune dysfunction and inflammation in antiretroviral therapy-treated individuals with undetectable viremia","volume":"229","author":"Benlarbi","year":"2024","journal-title":"J Infect Dis"},{"key":"2026031304525736300_jiaf461-B26","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1007\/s40121-023-00870-6","article-title":"Week 240 efficacy and safety of fostemsavir plus optimized background therapy in heavily treatment-experienced adults with HIV-1","volume":"12","author":"Aberg","year":"2023","journal-title":"Infect Dis Ther"},{"key":"2026031304525736300_jiaf461-B27","doi-asserted-by":"crossref","first-page":"1394644","DOI":"10.3389\/fimmu.2024.1394644","article-title":"Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study","volume":"15","author":"Llibre","year":"2024","journal-title":"Front Immunol"},{"key":"2026031304525736300_jiaf461-B28","doi-asserted-by":"crossref","first-page":"ofae469","DOI":"10.1093\/ofid\/ofae469","article-title":"Inflammatory biomarker reduction with fostemsavir over 96 weeks in heavily treatment-experienced adults with multidrug-resistant HIV-1 in the BRIGHTE study","volume":"11","author":"Clark","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026031304525736300_jiaf461-B29","doi-asserted-by":"crossref","first-page":"e080606","DOI":"10.1136\/bmjopen-2023-080606","article-title":"Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors","volume":"14","author":"Clemente","year":"2024","journal-title":"BMJ Open"},{"key":"2026031304525736300_jiaf461-B30","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study","volume":"382","author":"Cahn","year":"2013","journal-title":"Lancet"},{"key":"2026031304525736300_jiaf461-B31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jviromet.2015.02.017","article-title":"HIV-1 gp120 dimers decrease the overall affinity of gp120 preparations for CD4-induced ligands","volume":"215\u20136","author":"Coutu","year":"2015","journal-title":"J Virol Methods"},{"key":"2026031304525736300_jiaf461-B32","doi-asserted-by":"crossref","first-page":"710","DOI":"10.3390\/microorganisms8050710","article-title":"Elicitation of cluster A and co-receptor binding site antibodies are required to eliminate HIV-1 infected cells","volume":"8","author":"Beaudoin-Bussi\u00e8res","year":"2020","journal-title":"Microorganisms"},{"key":"2026031304525736300_jiaf461-B33","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1073\/pnas.1112391109","article-title":"Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops","volume":"109","author":"Kwon","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026031304525736300_jiaf461-B34","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.str.2016.03.005","article-title":"Paring down HIV env: design and crystal structure of a stabilized inner domain of HIV-1 gp120 displaying a major ADCC target of the A32 region","volume":"24","author":"Tolbert","year":"2016","journal-title":"Structure"},{"key":"2026031304525736300_jiaf461-B35","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/cid\/ciu038","article-title":"Long-term mortality in HIV-positive individuals virally suppressed for &gt;3 years with incomplete CD4 recovery","volume":"58","author":"Engsig","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2026031304525736300_jiaf461-B36","doi-asserted-by":"crossref","first-page":"e0160460","DOI":"10.1371\/journal.pone.0160460","article-title":"Cause-specific mortality in HIV-positive patients who survived ten years after starting antiretroviral therapy","volume":"11","author":"Trickey","year":"2016","journal-title":"PLoS One"},{"key":"2026031304525736300_jiaf461-B37","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1128\/jvi.65.9.4832-4838.1991","article-title":"Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies","volume":"65","author":"Xu","year":"1991","journal-title":"J Virol"},{"key":"2026031304525736300_jiaf461-B38","doi-asserted-by":"crossref","first-page":"12449","DOI":"10.1128\/JVI.01708-08","article-title":"Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia","volume":"82","author":"Tomaras","year":"2008","journal-title":"J Virol"},{"key":"2026031304525736300_jiaf461-B39","doi-asserted-by":"crossref","first-page":"e0096024","DOI":"10.1128\/jvi.00960-24","article-title":"Three families of CD4-induced antibodies are associated with the capacity of plasma from people living with HIV to mediate ADCC in the presence of CD4-mimetics","volume":"98","author":"Tauzin","year":"2024","journal-title":"J Virol"},{"key":"2026031304525736300_jiaf461-B40","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.3389\/fimmu.2017.01590","article-title":"Non-neutralizing antibodies directed against HIV and their functions","volume":"8","author":"Mayr","year":"2017","journal-title":"Front Immunol"},{"key":"2026031304525736300_jiaf461-B41","doi-asserted-by":"crossref","first-page":"e0182724","DOI":"10.1128\/mbio.01827-24","article-title":"CD4 downregulation precedes env expression and protects HIV-1-infected cells from ADCC mediated by non-neutralizing antibodies","volume":"15","author":"Richard","year":"2024","journal-title":"mBio"},{"key":"2026031304525736300_jiaf461-B42","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1128\/JVI.02898-15","article-title":"Development of broadly neutralizing antibodies and their mapping by monomeric gp120 in human immunodeficiency virus type 1-infected humans and simian-human immunodeficiency virus SHIVSF162P3N-infected macaques","volume":"90","author":"Jia","year":"2016","journal-title":"J Virol"},{"key":"2026031304525736300_jiaf461-B43","doi-asserted-by":"crossref","first-page":"12111","DOI":"10.1073\/pnas.1204533109","article-title":"HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120","volume":"109","author":"Kovacs","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026031304525736300_jiaf461-B44","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1038\/s41467-018-04758-9","article-title":"A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge","volume":"9","author":"Madani","year":"2018","journal-title":"Nat Commun"},{"key":"2026031304525736300_jiaf461-B45","doi-asserted-by":"crossref","first-page":"e00958-20","DOI":"10.1128\/JVI.00958-20","article-title":"Antigenicity and immunogenicity of HIV-1 envelope trimers complexed to a small-molecule viral entry inhibitor","volume":"94","author":"Alam","year":"2020","journal-title":"J Virol"},{"key":"2026031304525736300_jiaf461-B46","doi-asserted-by":"crossref","first-page":"e01325-19","DOI":"10.1128\/JVI.01325-19","article-title":"A new family of small-molecule CD4-mimetic compounds contacts highly conserved aspartic acid 368 of HIV-1 gp120 and mediates antibody-dependent cellular cytotoxicity","volume":"93","author":"Ding","year":"2019","journal-title":"J Virol"},{"key":"2026031304525736300_jiaf461-B47","doi-asserted-by":"crossref","first-page":"104072","DOI":"10.1016\/j.ebiom.2022.104072","article-title":"Predictive value of CD8+ T cell and CD4\/CD8 ratio at two years of successful ART in the risk of AIDS and non-AIDS events","volume":"80","author":"Serrano-Villar","year":"2022","journal-title":"EBioMedicine"},{"key":"2026031304525736300_jiaf461-B48","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/hiv.13700","article-title":"Immunological and virological response to fostemsavir in routine US clinical care: an OPERA cohort study","volume":"26","author":"Hsu","year":"2025","journal-title":"HIV Med"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf461\/64359558\/jiaf461.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/2\/247\/64359558\/jiaf461.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/2\/247\/64359558\/jiaf461.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:54:50Z","timestamp":1773392090000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/233\/2\/247\/8262780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":48,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,9,24]]},"published-print":{"date-parts":[[2026,2,18]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf461","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,15]]},"published":{"date-parts":[[2025,9,24]]}}}